RIBOSCIENCE ESMO PRESENTATION HIGHLIGHTS SAFETY, PK, PD AND EFFICACY DATA FROM THE FIRST 19 PATIENTS OF THE ENPP1 INHIBITOR RBS2418 PHASE 1 STUDY

/PRNewswire/ -- Riboscience, LLC, today announced the first presentation of data from the ongoing Phase 1 clinical trial of the ENPP1 inhibitor RBS2418 that...

Related Keywords

New York ,United States ,Klaus Klumpp ,Thomasu Marron ,European Society For Medical Oncology ,Prnewswire Riboscience ,Mount Sinai ,European Society ,Medical Oncology ,Subjects With ,Metastatic Tumors ,Text View ,Private Securities Litigation Reform Act ,Riboscience Llc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,